Zobrazeno 1 - 10
of 33
pro vyhledávání: '"David P. Benjamin"'
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 4, Pp 931-954 (2024)
Non-small cell lung cancer (NSCLC) that is operable still carries a high risk of recurrence, approaching 50% of all operable cases despite adding adjuvant chemotherapy. However, the utilization of immunotherapy and targeted therapy moving beyond the
Externí odkaz:
https://doaj.org/article/a13a8aa297834d64a480c690978c6548
Publikováno v:
Gynecologic Oncology Reports, Vol 52, Iss , Pp 101351- (2024)
Over the past five years (2019–2023), several new targeted therapies and immunotherapy has been approved in treating relapsed cervical, ovarian, and endometrial cancers. Concurrently, there has been growing recognition of financial toxicity associa
Externí odkaz:
https://doaj.org/article/35c284f0a0394c749d8a20258a150639
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Background Due to encouraging pre‐clinical data and supportive observational studies, there has been growing interest in applying cardiovascular drugs (including aspirin, angiotensin‐converting enzyme [ACE] inhibitors, statins, and metfo
Externí odkaz:
https://doaj.org/article/b7d28d4620fe493daf01d03b019e29e1
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Urachal cancer is a rare malignancy of the urachus that is treated with surgical resection if localized and systemic chemotherapy for metastatic disease. Circulating tumor DNA (ctDNA) is a single-stranded or double-stranded DNA released by tumor cell
Externí odkaz:
https://doaj.org/article/e9f5d0774374474092a723244ec66de5
Publikováno v:
Frontiers in Urology, Vol 4 (2024)
Externí odkaz:
https://doaj.org/article/6153cb17ee0347b083af5a68ca5adfa4
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 18 (2024)
Externí odkaz:
https://doaj.org/article/b430122248f2454bbd9715398983e18f
Autor:
Omid Yazdanpanah, Aditya Mahadevan, Aditi Sharma, David J. Benjamin, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Spinal cord compression (SCC) in metastatic prostate cancer (MPC) is a critical complication and multiple factors influence the optimal therapeutic strategy. We investigated the differences in practice patterns between teaching ho
Externí odkaz:
https://doaj.org/article/4c1cec9f20ae4dc8b28b340b4555869a
Autor:
Robert Hsu, David J. Benjamin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
In the past 15 years, non-small cell lung cancer (NSCLC) treatment has changed with the discovery of mutations and the development of new targeted therapies and immune checkpoint inhibitors. Epidermal growth factor receptor (EGFR) was the first mutat
Externí odkaz:
https://doaj.org/article/4145f65a24604133babc19ca3930e8b6
Autor:
David J. Benjamin, Robert Hsu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates.
Externí odkaz:
https://doaj.org/article/4bd3ab3f5d544039bc1eb26388b2b977
Publikováno v:
Cancer Medicine, Vol 11, Iss 18, Pp 3417-3424 (2022)
Abstract Purpose Patients with non‐small cell lung cancer (NSCLC) that harbor driver mutations are associated with a cancer diagnosis at a younger age. While targeted therapies provide deep remissions and durable benefit in a subset of patients, it
Externí odkaz:
https://doaj.org/article/12797c0e734a4d6e95b42e357d42f5fe